Search…

    Saved Articles

    You have not yet added any article to your bookmarks.

    Browse

    GDPR Compliance

    We use cookies to ensure you get the best experience on our website. By continuing to use our site, you accept our use of cookies, Privacy Policy, and Terms of Service.

    Zepbound beats Wegovy for weight loss in first head-to-head trial of blockbuster drugs

    2 days ago

    People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.
    Click here to Read more
    Prev Article
    New questions on White House's deal with China
    Next Article
    Trump to sign executive order slashing drug prices up to 80%

    Related Health Updates:

    Comments (0)

      Leave a Comment